Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells

Regenerative Medicine

Volumn 4, Issue 4, 2009, Pages 513-526

  Tseng, Su Yi ^a   Nishimoto, Kevin P ^a   Silk, Kathryn M ^b   Majumdar, Anish S ^a,c   Dawes, Glenn N ^a   Waldmann, Herman ^b   Fairchild, Paul J ^b   Lebkowski, Jane S ^a   Reddy, Anita ^a  

^a GERON CORPORATION   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c RELIANCE LIFE SCIENCES PVT LTD   (India)

Author keywords

Dendritic cells; Human embryonic stem cells; Immunotherapy; Monocytic cells; Vaccine

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; CD83 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E2; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BMP4 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; VACCINE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; EMBRYONIC STEM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MONOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; BIOTECHNOLOGY; CYTOLOGY; FLOW CYTOMETRY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

BIOTECHNOLOGY; BONE MORPHOGENETIC PROTEIN 4; CELL DIFFERENTIATION; DENDRITIC CELLS; EMBRYONIC STEM CELLS; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; STEM CELL FACTOR; T-LYMPHOCYTES; TELOMERASE; VACCINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349757819     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.09.25     Document Type: Article

References (22)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al.: Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
2. Murry CE, Keller G: Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132, 661-680 (2008).
3. Slukvin II, Vodyanik MA, Thomson JA, Gumenyuk ME, Choi KD: Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway. J. Immunol. 176, 2924-2932 (2006).
4. Senju S, Suemori H, Zembutsu H et al.: Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function. Stem Cells 25, 2720-2729 (2007).
5. Zhan X, Dravid G, Ye Z et al.: Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro. Lancet 364, 163-171 (2004).
6. Bandi S, Akkina R: Human embryonic stem cell (hES) derived dendritic cells are functionally normal and are susceptible to HIV-1 infection. AIDS Res. Ther. 5, 1 (2008).
7. Su Z, Frye C, Bae KM, Kelley V, Vieweg J: Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions. Clin. Cancer Res. 14, 6207-6217 (2008).
8. Karlsson KR, Cowley S, Martinez FO et al.: Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp. Hematol. 36, 1167-1175 (2008).
9. Xu C, Inokuma MS, Denham J et al.: Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 19, 971-974 (2001).
10. Li Y, Powell S, Brunette E, Lebkowski J, Mandalam R: Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. Biotechnol. Bioeng. 91, 688-698 (2005).
11. Okamura RM, Lebkowski J, Au M et al.: Immunological properties of human embryonic stem cell-derived oligodendrocyte progenitor cells. J. Neuroimmunol. 192, 134-144 (2007).
12. Jonuleit H, Kuhn U, Muller G et al.: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27, 3135-3142 (1997).
13. Minev B, Hipp J, Firat H et al.: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA 97, 4796-4801 (2000).
14. Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G: Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 109, 2679-2687 (2007).
15. Lugus JJ, Chung YS, Mills JC et al.: GATA2 functions at multiple steps in hemangioblast development and differentiation. Development 134, 393-405 (2007).
16. Eichmann A, Corbel C, Nataf V et al.: Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc. Natl Acad. Sci. USA 94, 5141-5146 (1997).
17. Fukuma D, Matsuyoshi H, Hirata S et al.: Cancer prevention with semi-allogeneic ES cell-derived dendritic cells. Biochem. Biophys. Res. Commun. 335, 5-13 (2005).
18. Avigan DE, Vasir B, George DJ et al.: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30, 749-761 (2007).
19. Gong J, Nikrui N, Chen D et al.: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165, 1705-1711 (2000).
20. Newton DA, Acierno PM, Brescia FJ, Brown EA, Gattoni-Celli S: Semi-allogeneic vaccines for patients with cancer and AIDS. J. Immunother. 25, 334-341 (2002).
21. Fabre JW: The allogeneic response and tumor immunity. Nat. Med. 7, 649-652 (2001).
22. Yasuda T, Kamigaki T, Kawasaki K et al.: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 56, 1025-1036 (2007).